JP2009543806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543806A5 JP2009543806A5 JP2009519695A JP2009519695A JP2009543806A5 JP 2009543806 A5 JP2009543806 A5 JP 2009543806A5 JP 2009519695 A JP2009519695 A JP 2009519695A JP 2009519695 A JP2009519695 A JP 2009519695A JP 2009543806 A5 JP2009543806 A5 JP 2009543806A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- receptor
- lyp
- gclq
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- -1 radionuclide Chemical compound 0.000 claims description 4
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229940055742 indium-111 Drugs 0.000 claims description 3
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 3
- 230000003278 mimic effect Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 claims description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 108010008940 LyP-1 peptide Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 108700011582 TER 286 Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229950000772 canfosfamide Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims 24
- 108020003175 receptors Proteins 0.000 claims 24
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80725506P | 2006-07-13 | 2006-07-13 | |
| PCT/US2007/073372 WO2008100328A2 (en) | 2006-07-13 | 2007-07-12 | METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012282110A Division JP2013060463A (ja) | 2006-07-13 | 2012-12-26 | ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009543806A JP2009543806A (ja) | 2009-12-10 |
| JP2009543806A5 true JP2009543806A5 (enExample) | 2010-09-02 |
Family
ID=39690654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519695A Pending JP2009543806A (ja) | 2006-07-13 | 2007-07-12 | ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物 |
| JP2012282110A Pending JP2013060463A (ja) | 2006-07-13 | 2012-12-26 | ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012282110A Pending JP2013060463A (ja) | 2006-07-13 | 2012-12-26 | ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8178104B2 (enExample) |
| EP (1) | EP2043696B1 (enExample) |
| JP (2) | JP2009543806A (enExample) |
| CA (1) | CA2657649A1 (enExample) |
| WO (1) | WO2008100328A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4903036B2 (ja) * | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | 血液脳関門を通過する担体としてのアプロチニンおよび類似体 |
| JP2010514839A (ja) * | 2007-01-03 | 2010-05-06 | バーナム インスティテュート フォー メディカル リサーチ | クロット結合化合物に関連する方法および組成物 |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2009092087A2 (en) * | 2008-01-18 | 2009-07-23 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
| US9732320B2 (en) | 2008-01-18 | 2017-08-15 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human TH17 cells |
| WO2009127072A1 (en) | 2008-04-18 | 2009-10-22 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2740317A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| WO2010111702A1 (en) * | 2009-03-27 | 2010-09-30 | The Research Foundation Of State University Of New York | Methods for preventing and treating angioedema |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| CN102869384B (zh) | 2009-06-22 | 2016-01-13 | 伯纳姆医学研究所 | 使用带有c-端元件的肽和蛋白质的方法和组合物 |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US20110262347A1 (en) | 2010-04-08 | 2011-10-27 | The Salk Institute For Biological Studies | Methods and compositions for enhanced delivery of compounds |
| EP2715291A4 (en) | 2011-05-31 | 2015-10-21 | Airware Inc | NON-DISPERSIVE GAS SENSORS WITH ABSORPTION INFRARED ABSORPTION (NDIR) |
| US9061079B2 (en) * | 2011-06-24 | 2015-06-23 | Sanford-Burnham Medical Research Institute | Peptides that home to atherosclerotic plaques and methods of use |
| GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
| WO2016172515A1 (en) * | 2015-04-23 | 2016-10-27 | Sanford Burnham Prebys Medical Discovery Institute | Targeted delivery system and methods of use therefor |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| KR102061924B1 (ko) | 2015-11-24 | 2020-01-02 | 강원대학교산학협력단 | Ｐ３２ 저해제를 포함하는 심혈관 질환 예방 또는 치료용 조성물 |
| AU2019347666B2 (en) * | 2018-09-28 | 2025-10-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| KR20230037532A (ko) * | 2020-06-02 | 2023-03-16 | 다이내믹큐어 바이오테크놀로지 엘엘씨 | 항-cd93 구축물 및 그의 용도 |
| KR20230133832A (ko) * | 2020-07-29 | 2023-09-19 | 다이내믹큐어 바이오테크놀로지 엘엘씨 | 항-cd93 구축물 및 그의 용도 |
| KR102739370B1 (ko) * | 2021-10-01 | 2024-12-05 | 강원대학교산학협력단 | p32 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물 |
| KR102841756B1 (ko) * | 2021-10-01 | 2025-08-01 | 강원대학교산학협력단 | 알기나제 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물 |
| WO2023064887A1 (en) | 2021-10-15 | 2023-04-20 | The Board Of Trustees Of The University Of Illinois | Mechanochemical dynamic therapy for focal cancer treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3040693A (en) * | 1961-02-20 | 1962-06-26 | George F Bunker | Oar paddle, boat hook and oar |
| US5691447A (en) * | 1995-03-24 | 1997-11-25 | Tanox Biosystems, Inc. | GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies |
| AU6425800A (en) * | 1999-06-30 | 2001-01-22 | Max-Delbruck-Centrum Fur Molekulare Medizin | Agents for the diagnosis, prognosis and treatment of malignant diseases |
| US7192921B2 (en) * | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
| JP2005514348A (ja) * | 2001-11-08 | 2005-05-19 | ザ バーナム インスティチュート | 腫瘍リンパ性脈管構造を目指すペプチドおよびその使用方法 |
| US20060286545A1 (en) * | 2003-05-23 | 2006-12-21 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
-
2007
- 2007-07-12 CA CA002657649A patent/CA2657649A1/en not_active Abandoned
- 2007-07-12 EP EP07872694.0A patent/EP2043696B1/en not_active Not-in-force
- 2007-07-12 JP JP2009519695A patent/JP2009543806A/ja active Pending
- 2007-07-12 WO PCT/US2007/073372 patent/WO2008100328A2/en not_active Ceased
- 2007-07-13 US US11/777,382 patent/US8178104B2/en not_active Expired - Fee Related
-
2012
- 2012-04-17 US US13/448,820 patent/US20120219502A1/en not_active Abandoned
- 2012-12-26 JP JP2012282110A patent/JP2013060463A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543806A5 (enExample) | ||
| US8461119B2 (en) | Agents that modulate Eph receptor activity | |
| ES2601352T3 (es) | Cribado para compuestos anti-cáncer usando actividad de netrina-1 | |
| US7999069B2 (en) | EphB receptor-binding peptides | |
| US20220306688A1 (en) | KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto | |
| US11371994B2 (en) | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | |
| JP2008515876A (ja) | イメージング及び治療用のイメージング及び治療のエンドキットにおけるシュタウディンガーライゲーションの使用 | |
| JP2009507833A5 (enExample) | ||
| JP2009544284A5 (enExample) | ||
| US20140186850A1 (en) | Reagents and methods for bispecific antibody-based binding of target molecules | |
| CA2893280A1 (en) | Compositions and methods for the treatment of cancers associated with a deficiency in the mre11/rad50/nbs1 dna damage repair complex | |
| US20150355187A1 (en) | Mixed payload containing polymers and use thereof | |
| US20210292762A1 (en) | Icam-1 aptamers, diagnostic and therapeutic uses thereof | |
| US11293925B2 (en) | Identifying amyloidogenic proteins and amyloidogenic risk | |
| EP1852441A2 (en) | Agents that modulate EPH receptor activity | |
| CN118931908B (zh) | 一种结合蛋白磷酸酶1调节亚基26蛋白的核酸适配体、筛选方法及其应用 | |
| JP2003261567A (ja) | グアニンバルジ修飾分子 | |
| Heston | New Imaging Strategies for Prostate Cancer | |
| Sett | Aptamers for breast cancer protein markers | |
| JP2005522226A5 (enExample) | ||
| Williams | Designing recognition elements based on DNA scaffolds | |
| Wichert | DNA-encoded self-assembling chemical library technology for de novo ligand discovery and tumor targeting applications | |
| Lee | Part 1: Isolation of Orexin Receptor Regulators via a Microarray-Based, Two-Color Cell Binding Screen. Part II: Targeted Inactivation of Proteins triggered by Visible Light. | |
| Acharya | Modeling the transport and inhibition kinetics of the human multidrug resistance transporter P-glycoprotein in MDCK-II cells | |
| HK1109904A (en) | Agents that modulate eph receptor activity |